Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706261 · ClinicalTrials.gov registry record · Phase 1
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
A Phase 1 study of Alzheimer Disease, sponsored by Adam Brickman.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 1
- Study location
NCT03706261 is a Phase 1 study of Alzheimer Disease that has completed, run by Adam Brickman. The registered enrollment target is 145 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03706261, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Adam Brickman.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 1
- Study location
Study Summary
The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across racial/ethnic groups, and the relationship between MRI markers of small-vessel cerebrovascular disease and tau pathology. The study also investigates amyloid-dependent tau spreading.
Conditions Studied
Interventions
- DRUG 18F-MK-6240
- DRUG 18F-Florbetaben
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03706261
The ClinicalTrials.gov registry entry for NCT03706261 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower). The listed sponsor is Adam Brickman, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which 18F-MK-6240 is the first listed.
NCT03706261 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03706261 about?
NCT03706261 is a clinical study titled "Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults". The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across racial/ethnic groups, and the relationship between MRI markers of small-v...
What is the current status of trial NCT03706261?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2019-03-22. Estimated completion is 2023-07-14.
What conditions does trial NCT03706261 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03706261?
The interventions under investigation include: 18F-MK-6240 (DRUG), 18F-Florbetaben (DRUG).
Who is sponsoring clinical trial NCT03706261?
This trial is sponsored by Adam Brickman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03706261 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.